Treatment of the early stages of Parkinson's disease. Differences in approaches to the choice of therapy in different countries

Abstract

The review addresses an approach to the treatment of early stages of Parkinson's disease (PD) and also provides data on the real-life use of different classes of drugs for the treatment of PD in comparison with other countries, as well as data from an all-Russian survey of patients with PD. In our country, dopamine receptor agonists (DRAs) are currently one of the most commonly prescribed groups of drugs in the treatment of early stages of PD. According to international studies, there is still insufficient information on the use of different classes of drugs in practice for the treatment of PD and studies on the real-life practice of prescribing them. Prescribing the first drug for the treatment of early PD should be the result of an informed shared decision between doctor and patient, in which the patient plays a crucial role. Piribedil, one of the oldest drugs for the treatment of PD and still one of the most commonly prescribed drugs for the treatment of early stages of PD, was found to be superior to other DRAs in a recent meta-analysis (2023).

Keywords

• parkinson's disease
• treatment of the early stages of parkinson's disease